Company news

Galectin Therapeutics Inc. news in 2026

Galectin Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026

November 5, 2026

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

October 6, 2026

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

August 14, 2026

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

August 4, 2026

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

June 22, 2026

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis

May 27, 2026

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

May 15, 2026

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology

May 10, 2026

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

March 30, 2026

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

March 16, 2026

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12: 00 PM ET

February 26, 2026

Decks in 2026